본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

European journal of cancer v.93, 2018년, pp.79 - 88   SCI SCIE SCOPUS
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)

Hagiwara, Yasuhiro (Department of Biostatistics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan ) ; Ohashi, Yasuo (Department of Integrated Science and Engineering for Sustainable Society, Chuo University, 1-13-27 Kasuga, Bunkyo, Tokyo 112-8551, Japan ) ; Uesaka, Katsuhiko (Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, 1007 Shimo-Nagakubo, Nagaizumi, Sunto, Shizuoka 411-8777, Japan ) ; Boku, Narikazu (Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo, Tokyo 104-0045, Japan ) ; Fukutomi, Akira (Division of Gastrointestinal Oncology, Shizuoka Cancer Center Hospital, 1007 Shimo-Nagakubo, Nagaizumi, Sunto, Shizuoka 411-8777, Japan ) ; Okamura, Yukiyasu (Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, 1007 Shimo-Nagakubo, Nagaizumi, Sunto, Shizuoka 411-8777, Japan ) ; Konishi, Masaru (Department of Hepatobiliary-Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan ) ; Matsumoto, Ippei (Division of Hepato-Biliary-Pancreatic Sur ) ; Kaneoka, Yuji ; Shimizu, Yasuhiro ; Nakamori, Shoji ; Sakamoto, Hirohiko ; Morinaga, Soichiro ; Kainuma, Osamu ; Imai, Koji ; Sata, Naohiro ; Hishinuma, Shoichi ; Ojima, Hitoshi ; Yamaguchi, Ryuzo ; Hirano, Satoshi ; Sudo, Takeshi ;
  • 초록  

    Abstract Background Adjuvant chemotherapy with S-1 for resected pancreatic cancer demonstrated survival benefits compared with gemcitabine in the JASPAC 01 trial. We investigated the effect of these agents on health-related quality of life (HRQOL) of patients in the JASPAC 01 trial. Methods Patients with resected pancreatic cancer were randomly assigned to receive gemcitabine (1000 mg/m 2 weekly for three of four weeks for up to six cycles) or S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles). HRQOL was assessed using the EuroQol-5D-3L (EQ-5D) questionnaire at baseline, months three and six, and every 6 months thereafter. HRQOL end-points included change in EQ-5D index from baseline, responses to five items in the EQ-5D, and quality-adjusted life months up to 24 months. Results Of randomised 385 patients, 354 patients were included in HRQOL analysis. Mean change in the EQ-5D index was similar in the S-1 and gemcitabine groups within 6 months from treatment initiation (difference, 0.024; P = 0.112), whereas corresponding mean from 12 to 24 months was better in the S-1 group than in the gemcitabine group (difference, 0.071; P P Conclusion Adjuvant chemotherapy with S-1 does not improve HRQOL within 6 months from treatment initiation but does improve HRQOL thereafter and quality-adjusted life months. Clinical trial registration number UMIN000000655 at UMIN CTR. Highlights Health-related quality of life (HRQOL) in the JASPAC 01 trial was analysed. The trial compared adjuvant S-1 with gemcitabine for resected pancreatic cancer. HRQOL within 6 months was similar between the two treatments. HRQOL from 12 to 24 months was better with S-1 than with gemcitabine. Quality-adjusted life months were longer with S-1 than with gemcitabine.


  • 주제어

    Adjuvant chemotherapy .   Clinical trial .   Phase III .   Gemcitabine .   Pancreatic cancer .   Health-related quality of life .   S-1 (combination).  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기